GSK Medicine: Study No.: Title: Rationale: Objectives: Indication: Study Investigators/Centers: Research Methods:
|
|
- Karen Banks
- 6 years ago
- Views:
Transcription
1 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country. GSK Medicine: Rosiglitazone,rosiglitazone/metformin,rosiglitazone/glimepiride Study No.: WWE113497/WEUS253 Title: Incidence of Neoplasms in Rosiglitazone Clinical Trials Rationale: This study was an updated analysis of all reports of neoplasms in rosiglitazone s (RSG) clinical trials database (including double blind and open label extension studies) as of 11/04/2004, undertaken to address regulatory concerns regarding the PPAR agonists and carcinogenicity and to update a previous evaluation of RSG and neoplasms. Objectives: Specific objectives of the study were: 1. To determine the incidence rates of various neoplasms (malignant, benign and unspecified) in the RSG clinical trial database and for comparator arms (placebo or active therapies). 2. To determine the incidence rates of various neoplasms (malignant, benign and unspecified) in the RSG clinical trial database over time to determine if the rate of certain neoplasms of interest increases over time. 3. To determine the incidence rates of neoplasms of special interest, including malignant bladder, colorectal, liver, pancreas, breast, kidney, and prostate neoplasms. 4. To compare the incidence rate of neoplasms in RSG clinical trial program to the incidence rate obtained from Surveillance, Epidemiology and End Results (SEER) Indication: Type 2 Diabetes Study Investigators/Centers: GSK Research Methods: Data Source: The validated database used contains data as of 11/04/2004, and includes information on 9,542 RSG treated subjects (9,704 patient-years of exposure) who were on treatment for an average of 12.2 months. The RSG clinical trial database includes 755 subjects on placebo (221 patient-years) and 4062 subjects treated with other comparator antidiabetic drugs (2219 patient-years). The patients on comparator antidiabetic drugs were on therapy for an average of 6.6 months and those on placebo for a mean of 3.5 months. Study Design: Retrospective analysis of integrated clinical trials data Study Population: Type 2 diabetic patients who were on RSG, placebo, or other comparator antidiabetic drugs. Study Exposures, Outcomes: Exposures Exposure was defined as receiving RSG, placebo, or other antidiabetic drugs. For the analysis, study subjects were categorized into either RSG or non-rsg. The RSG arm includes all subjects who received one of the following regimens: RSG Monotherapy; RSG+Sulphonyurea (SU); RSG+Metfromin (MET); RSG+Insulin; RSG+SU+MET. The non-rsg arm includes subjects who received one of the following regimens: SU Monotherapy; MET Monotherapy; Insulin Monotherapy; SU+MET. Outcome Definitions Neoplasm in Clinical Trials The outcomes of the study are malignant, benign, and unspecified neoplasms. All neoplasms coded to MedDRA System Organ Class (SOC) of neoplasms benign, malignant and unspecified (including cysts and polyps) were captured. In addition, events mapping to the following SOC(s) of gastrointestinal disorders, reproductive system and breast disorders and skin and subcutaneous tissue disorders were reviewed and non-malignant tumors (e.g., polyps) were identified and compiled. Neoplasm of Special interest Neoplams of special interest that were assessed in this analysis include the following malignant neoplasms: bladder, colorectal, liver, pancreas, breast, kidney, and prostate.
2 Data Analysis Methods: The incidence rates of neoplasms (benign, malignant and unspecified) per 100 patient years were calculated with corresponding 95% confidence intervals (CIs). Life tables were constructed to examine the incidence rate of neoplasms (benign, malignant and unspecified) and neoplasms of special interest over time in rosiglitazone treated patients. Neoplasm Rates Observed in Clinical Trials Comopared to SEER The incidence rates of neoplasms in the RSG program were compared with published epidemiological data. National cancer incidence rates were obtained from the Surveillance, Epidemiology, and End Results (SEER) program's 2001 data. The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute is an authoritative source of information on cancer incidence and survival in the United States. The SEER Program currently collects and publishes cancer incidence and survival data from 14 population-based cancer registries and three supplemental registries covering approximately 26 percent of the US population. Information on more than 3 million in situ and invasive cancer cases is included in the SEER database, and approximately 170,000 new cases are added each year within the SEER coverage areas. The SEER Registries routinely collect data on patient demographics, primary tumor site, morphology, stage at diagnosis, first course of treatment, and follow-up for vital status. The SEER Program is the only comprehensive source of population-based information in the United States that includes stage of cancer at the time of diagnosis and survival rates within each stage. The SEER program is considered the standard for quality among cancer registries around the world. The number of expected cases was calculated by multiplying age-specific national incidence rates by the percentage of RSG treated patients in each age group from the RSG clinical trial database. Standardized incidence ratios (SIRs) were calculated by dividing the total number of observed cases per 100,000 subjects by the total number of expected cases per 100,000 subjects. Limitations: The total number of subjects and the average length of observation (exposure) per subject were considerably greater for subjects in the RSG group compared to placebo and other comparator arms. The incidence rate of most tumors increases with age so that longer observation periods are expected to yield a greater number of events. These studies were not intended to access the incidence of new onset tumors and therefore no screening for previously undiagnosed tumors was implemented and reported tumor events were not necessarily confirmed or adjudicated. The latency period for the effect of some carcinogens can be as long as 15 to 20 years; although, observed associations between carcinogens and cancer can also be observed in much shorter time frames. The analysis is limited by the follow-up available in the RSG clinical trial database. Finally, the RSG clinical trial database has undergone migration from WHO to MedDRA. The clinical team has identified some instances where the MedDRA preferred term selected in the recoding processes were less specific than one might expect based on verbatim terms reported by the investigators. It remains unclear whether or not this conversion impacts the results of this study. Study Results: Exposure to Rosiglitazone, placebo and comparator agents in the RSG clinical trial database Table 1 gives the total number of subjects exposed to RSG, placebo and comparator agents as well as the total patient-years of exposure. Incidence rates Table 2 provides the incidence rates of malignant, benign and unspecified neoplasms for RSG exposed subjects compared to non-rsg exposed subjects. Neoplasm (malignant, benign and unspecified) in Clinical Trials In the current database population, where there is considerably longer exposure to RSG compared to the active comparator groups and placebo, the incidence rates of neoplasms (benign, malignant and unspecified) per 100 patient years were generally similar in all treatment regimens examined in Tables 3A 3C. The confidence intervals for the RSG group are entirely contained by, or overlap with the confidence intervals for the non-rsg group. For some specific types of neoplasms, there were no cases or only isolated reports of these tumors in the RSG or the comparator group and therefore comparing the incidence rates was not possible. The crude rate of
3 neoplasms in all RSG exposed patients [1.610 per 100 patient-years (95% C.I. = ) for malignant neoplasms (Table 3A), per 100 patient-years (95% C.I. = ) for benign neoplasms (Table 3B) and per 100 patient-years (95% C.I. = ) for unspecified neoplasms (Table 3C)] was similar to that of the all non-rsg group [1.438 per 100 patient-years (95% C.I. = ) for malignant neoplasms (Table 3A), per 100 patient-years (95% C.I. = ) for benign neoplasms (Table 3B) and per 100 patientyears (95% C.I. = ) for unspecified neoplasms (Table 3C)] as summarized in table 2 below. Incidence rate of malignant, benign, and unspecified neoplasms over time There was no increase in the estimated incidence rate for malignant, benign and unspecified neoplasms in this database over the 4.50 years of follow-up (Tables 4A 4C). Neoplasm of Special Interest There does not appear to be a trend towards an increase in the estimated rate of any of the above mentioned neoplasms of interest over time (Data not shown). Neoplasm Rates Observed in Clinical Trials Compared to SEER Diabetes has been associated with an increased risk for a variety of malignancies (Table 5). The standardized incidence ratio compares the number of observed cases to the number of expected cases according to SEER 2001 (Table 6). Importantly, the expected cases from SEER are the number of expected cases of malignant neoplasms for the general population and not for a diabetic population. Given that the incidence rate of certain cancers appears to be elevated for diabetic patients (see Table 5), the expected number of cases according to SEER will underestimate the expected number of cases for the diabetic population participating in the RSG clinical trials program. The SIRs in Table 6 indicate that the incidence rate of malignant bladder, colorectal, liver, melanoma, pancreatic neoplasms in T2DM population receiving RSG was greater than expected based on data for the general population. However, the magnitude of the increases observed are generally consistent with data in the published literature demonstrating an increased risk for colorectal, liver and pancreatic cancer in patients with T2DM (see Table 5). For subjects treated with RSG, the incidence rates of breast, kidney and prostate malignant neoplasms are lower than the general population. The lower incidence rates of breast and prostate cancer are consistent with data from the literature (Table 5); in contrast to the incidence rate of kidney cancer which appears to be elevated in type 2 diabetic patients relative to the general population. A non-statistically significant 2.23-fold increase in the incidence rate of malignant melanoma was observed. The study further investigated the observed 2.23-fold higher incidence rate of malignant melanoma in the RSG clinical trial database compared to SEER The currently available published data is minimal and not robust enough to ascertain if there is an increased rate of melanoma in the diabetic population. Considering this, the Aetna database 1 was evaluated to assess the relationship, if any, between type 2 diabetes mellitus and melanoma. In the Aetna study, the risk of melanoma was higher in the diabetic population compared to the general population (adjusted relative risk = 1.63; 95% CI = ). Further, the incidence rate of melanoma is known to be higher in Caucasians. Given that 74% of subjects in the RSG clinical trial database are White, the standardized incidence ratios for malignant melanoma was recalculated after stratifying by ethnicity. The SIR for malignant melanoma for Whites was still elevated and non-significant (SIR = 1.90, 95% CI =0.70, 4.14). It is consistent with the increased risk of melanoma for diabetic subjects observed in the Aetna study. Conclusion: The incidence rate per 100 patient years of exposure for any malignant, benign or unspecified neoplasm was similar for RSG and non-rsg treatment regimens. There was no trend for increased incidence of any malignant, benign, or unspecified neoplasm with rosiglitazone therapy over time. The very small number of events for some specific tumors makes the incidence rate unstable and significantly limits any conclusions regarding possible differences between treatments. The SIR for cancers associated with diabetes was similarly increased in RSG treated subjects versus the SEER database. 1 Oliveria SA, Koro CE, Ulcickas Yood M, Sowell M. Cancer Incidence among Patients Treated with Antidiabetic Pharmacotherapy. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2008;2(1):47-57
4 Date updated: 04-Jun-2008
5 Table 1: Exposure to antidiabetic drugs and placebo in the RSG clinical trial database as of November 4th 2004 Group # of Pts Mean length of exposure (+-SD) in months Median length of exposure in months Total PY exposure All RSG* (±2.34) All NON RSG* (± 4.78) Placebo (± 2.36) Active Comparator* (± 4.96) *All RSG= RSG mono, RSG+SU, RSG+MET, RSG+Insulin, RSG+SU+MET All NON-RSG= Placebo, SU Mono, MET Mono, SU+MET, Insulin Mono Active comparator = SU Mono, MET Mono, SU+MET, Insulin Mono
6 Table 2: Incidence rates of malignant, benign and unspecified Neoplasms comparing RSG to non-rsg exposure categories in the RSG clinical trial database as of November 4th 2004 Incidence Rate per 100 patient-years All RSG All NON RSG Malignant Neoplasms ( ) ( ) Benign Neoplasms ( ) ( ) Unspecified Neoplasms ( ) ( )
7 Table 3A: Incidence Rates of Malignant Neoplasms Per 100 Patient-years by Exposure Category Category All RSG 9542 (9704.0) All NON-RSG 4817 (2439.8) Any case (155) ( ) Basal cell-skin (31) ( ) Bladder (6) ( ) Breast* (9) ( ) Colorectal (11) ( ) Esophagus (4) ( ) Kidney (2) ( ) Larynx (1) ( ) Leiomyosarcoma (1) ( ) Leukemia (3) ( ) Liver (5) ( ) Lung (15) ( ) Lymphoma (2) ( ) Myeloma (3) ( ) Ovary* (2) ( ) Pancreas (5) ( ) Pharynx (1) ( ) (35) ( ) (8) ( ) (2) ( ) (2) ( ) (1) ( ) (2) ( ) (4) ( ) (1) ( ) (1) ( )
8 Category All RSG 9542 (9704.0) All NON-RSG 4817 (2439.8) Prostate** (21) ( ) Skin (2) ( ) Skin-Melanoma (7) ( ) (6) ( ) Spleen (1) ( ) Stomach (4) ( ) Unspecified Primary (7) ( ) Unspecified Site (19) ( ) (2) ( ) (5) ( ) Uterus* (2) ( ) (1) ( ) * Patient-years for females; ** Patient-years for males All RSG= RSG mono, RSG+SU,RSG+MET,RSG+Insulin,RSG+SU+MET N = number of patient; Pt-Yr = patients-year; = none reported ; Values of are actually < Two patients were excluded due to missing onset day (one with benign skin neoplasm and one with malignant esophagus cancer)
9 Table 3B: Incidence Rates of Benign Neoplasms Per 100 Patient-years by Exposure Category Category All RSG 9542 (9704.0) All NON-RSG 4817 (2439.8) Bladder (3) ( ) Breast* (7) ( ) CNS-meninges (3) ( ) Colo-rectal (17) ( ) Eye (2) ( ) Hemangioma (2) ( ) Lipoma (29) ( ) Neuroma (1) ( ) (2) ( ) (1) ( ) (2) ( ) (1) ( ) Ovary* (1) ( ) Parathyroid (1) ( ) Prostate** (4) ( ) Skin (32) ( ) Unspecified Site (4) ( ) (6) ( ) (3) ( ) Uterus* (13) ( ) (5) ( ) * Patient-years for females; ** Patient-years for males All RSG= RSG mono, RSG+SU,RSG+MET,RSG+Insulin,RSG+SU+MET N = number of patient; Pt-Yr = patients-year; = none reported; Values of are actually < Two patients were excluded due to missing onset day (one with benign skin neoplasm and one with malignant esophagus cancer)
10 Table 3C: Incidence Rates of Unspecified Neoplasms Per 100 Patient-years by Exposure Category Category All RSG 9542 (9704.0) All NON-RSG 4817 (2439.8) Any case (45) ( ) Colo-rectal (29) ( ) Kidney (2) ( ) Lung (2) ( ) Mouth (1) ( ) Thyroid (7) ( ) Unspecified Site (1) ( ) (11) ( ) (9) ( ) (1) ( ) (1) ( ) Upper GI Polyp (4) ( ) * Patient-years for females; ** Patient-years for males All RSG= RSG mono, RSG+SU,RSG+MET,RSG+Insulin,RSG+SU+MET Pt-Yr = patients-year; = none reported; = none reported; Values of are actually < Two patients were excluded due to missing onset day (one with benign skin neoplasm and one with malignant esophagus cancer).
11 Table 4A: Life Table for All Malignant Neoplasms in Rosiglitazone Treated Patients (N = 9542) Interval in Years (Lower-Upper) Number Failed Number Censored Hazard* Standard Error * Hazard = instantaneous probability of adverse events in question Two patients were excluded due to missing onset day (one with benign skin neoplasm and one with malignant esophagus cancer)
12 Table 4B: Life Table for All Benign Neoplasms in Rosiglitazone Treated Patients (N = 9542) Interval in Years (Lower-Upper) Number Failed Number Censored Hazard* Standard Error * Hazard = instantaneous probability of adverse events in question Two patients were excluded due to missing onset day (one with benign skin neoplasm and one with malignant esophagus cancer)
13 Table 4C: Life Table for All Unspecified Neoplasms in Rosiglitazone Treated Patients (N = 9542) Interval in Years (Lower-Upper) Number Failed Number Censored Hazard* Standard Error * Hazard = instantaneous probability of adverse events in question Two patients were excluded due to missing onset day (one with benign skin neoplasm and one with malignant esophagus cancer)
14 Table 5: The Relative Risk of Various Malignant Cancers of Interest in the Diabetic Compared to the General Population* Malignant Cancer Relative Risk Bladder Colorectal Liver Pancreas Breast Kidney Prostate *For a complete review and references, refer to the report The Incidence of Cancer in the Diabetic Population generated on June 30 th 2004 (UM2005/00187/00).
15 Table 6: Standardized Incidence Ratios (SIRs) for Malignant Neoplasms in Rosiglitazone Treated Patients Compared to SEER 2001 Site Observed Rate per 100,000 subjects Expected Rate per 100,000 subjects*** SIR 95% CI Colorectal , 1.74 Bladder , 2.93 Breast* , 1.44 Liver ,10.46 Lung , 1.55 Pancreas , 4.94 Prostate** , 1.13 Kidney , 2.79 Melanoma , 4.60 * Female Patients ** Male Patients *** Based on SEER incidence 2001
Estimated Minnesota Cancer Prevalence, January 1, MCSS Epidemiology Report 04:2. April 2004
MCSS Epidemiology Report 04:2 Suggested citation Perkins C, Bushhouse S.. Minnesota Cancer Surveillance System. Minneapolis, MN, http://www.health.state.mn.us/divs/hpcd/ cdee/mcss),. 1 Background Cancer
More informationEpidemiology in Texas 2006 Annual Report. Cancer
Epidemiology in Texas 2006 Annual Report Cancer Epidemiology in Texas 2006 Annual Report Page 94 Cancer Incidence and Mortality in Texas, 2000-2004 The Texas Department of State Health Services Texas Cancer
More informationCancer in Ontario. 1 in 2. Ontarians will develop cancer in their lifetime. 1 in 4. Ontarians will die from cancer
Cancer in Ontario 1 in 2 Ontarians will develop cancer in their lifetime 1 in 4 Ontarians will die from cancer 14 ONTARIO CANCER STATISTICS 2016 1 Cancer in Ontario An overview Cancer is a group of more
More informationTHE BURDEN OF CANCER IN NEBRASKA: RECENT INCIDENCE AND MORTALITY DATA
THE BURDEN OF CANCER IN NEBRASKA: RECENT INCIDENCE AND MORTALITY DATA Presented by: Bryan Rettig, MS Nebraska Dept. of Health & Human Services Division of Public Health May 31, 2017 Nebraska Cancer Registry
More informationCancer prevalence. Chapter 7
Chapter 7 Cancer prevalence Prevalence measures the number of people diagnosed with cancer who are still alive. This chapter presents current and historical statistics on cancer prevalence in Ontario.
More informationDATA UPDATE: CANCER INCIDENCE IN DAKOTA AND WASHINGTON COUNTIES
DATA UPDATE: CANCER INCIDENCE IN DAKOTA AND WASHINGTON COUNTIES MCSS Epidemiology Report 2015:1 May 13, 2015 Minnesota Cancer Surveillance System Chronic Disease and Environmental Epidemiology Section
More informationConstruction of a North American Cancer Survival Index to Measure Progress of Cancer Control Efforts
Construction of a North American Cancer Survival Index to Measure Progress of Cancer Control Efforts Chris Johnson, Cancer Data Registry of Idaho NAACCR 2016 Annual Conference June 14, 2016 Concurrent
More informationDATA UPDATE: CANCER INCIDENCE IN DAKOTA AND WASHINGTON COUNTIES
This document is made available electronically by the Minnesota Legislative Reference Library as part of an ongoing digital archiving project. http://www.leg.state.mn.us/lrl/lrl.asp DATA UPDATE: CANCER
More informationHazelinks - Cancer incidence analysis (First data extraction)
Hazelinks - Cancer incidence analysis (First data extraction) Authors Prof Malcolm Sim Ms Christina Dimitriadis Dr Caroline Gao Mr Anthony Del Monaco 1 1 Contents Abbreviations... 3 Executive Summary...
More informationNational Cancer Statistics in Korea, 2014
National Cancer Statistics in Korea, 2014 2016. 12. 20. Korea Central Cancer Registry Cancer Incidence in Korea, 2014 National Cancer Incidence, 2014 Trends in Cancer Incidence by Sex and Year * Dark colored
More informationAnnual Report to the Nation on the Status of Cancer, , Featuring Survival Questions and Answers
EMBARGOED FOR RELEASE CONTACT: Friday, March 31, 2017 NCI Media Relations Branch: (301) 496-6641 or 10:00 am EDT ncipressofficers@mail.nih.gov NAACCR: (217) 698-0800 or bkohler@naaccr.org ACS Press Office:
More informationANNUAL CANCER REGISTRY REPORT-2005
ANNUAL CANCER REGISTRY REPORT-25 CANCER STATISTICS Distribution of neoplasms Of a total of 3,115 new neoplasms diagnosed or treated at the Hospital from January 25 to December, 25, 1,473 were seen in males
More informationSMOKING AND CANCER RISK
SMOKING AND CANCER RISK The effects of smoking on health were documented in a landmark report by the Surgeon General in 1964. Since then the devastating effect from smoking on millions of American lives
More informationCancer in Estonia 2014
Cancer in Estonia 2014 Estonian Cancer Registry (ECR) is a population-based registry that collects data on all cancer cases in Estonia. More information about ECR is available at the webpage of National
More informationCancer in Ireland : Annual Report of the National Cancer Registry
Cancer in Ireland 1994-213: Annual Report of the National Cancer Registry 215 Page 3 ABBREVIATIONS 95% CI 95% confidence interval APC Annual percentage change ASR Age-standardised rate (European standard
More informationImpact and implications of Cancer Death Status Reporting Delay on Population- Based Relative Survival Analysis with Presumed-Alive Assumption
Impact and implications of Cancer Death Status Reporting Delay on Population- Based Relative Survival Analysis with Presumed-Alive Assumption X Dong, Y Ren, R Wilson, and K Zhang NAACCR 6-20-2017 Introduction
More informationSamuel M. Lesko, MD, MPH Director of Research/Medical Director
Cancer in Northeastern Pennsylvania: Incidence, Mortality and Survival for Common Cancers Samuel M. Lesko, MD, MPH Director of Research/Medical Director May 11 334 Jefferson Avenue, Scranton, PA 1851-57-941-7984
More informationSupplementary Online Content
Supplementary Online Content Henson KE, Brock R, Charnock J, Wickramasinghe B, Will O, Pitman A. Risk of suicide after cancer diagnosis in England. JAMA Psychiatry. Published online November 21, 2018.
More informationAPPENDIX ONE: ICD CODES
APPENDIX ONE: ICD CODES ICD-10-AM ICD-9-CM Malignant neoplasms C00 C97 140 208, 238.6, 273.3 Lip, oral cavity and pharynx C00 C14 140 149 Digestive organs C15 C26 150 157, 159 Oesophagus 4 C15 150 excluding
More information*
Introduction Cancer is complex, can have many possible causes, and is increasingly common. For the U.S. population, 1 in 2 males and 1 in 3 females is at risk of developing cancer in their lifetime. The
More informationCANCER FACTS & FIGURES For African Americans
CANCER FACTS & FIGURES For African Americans Pennsylvania, 2006 Pennsylvania Cancer Registry Bureau of Health Statistics and Research Contents Data Hightlights...1 Pennsylvania and U.S. Comparison...5
More informationSMOKING AND CANCER RISK
SMOKING AND CANCER RISK The effects of smoking on health were documented in a landmark report by the Surgeon General in 1964. Since then the devastating effect from smoking on millions of American lives
More informationCancer in the Northern Territory :
Cancer in the Northern Territory 1991 21: Incidence, mortality and survival Xiaohua Zhang John Condon Karen Dempsey Lindy Garling Acknowledgements The authors are grateful to the many people, who have
More informationTruman Medical Center-Hospital Hill Cancer Registry 2014 Statistical Summary Incidence
Truman Medical Center-Hospital Hill Cancer Registry 2014 Statistical Summary Incidence In 2014, there were 452 new cancer cases diagnosed and or treated at Truman Medical Center- Hospital Hill and an additional
More informationCancer in Ireland : Annual Report of the National Cancer Registry
Cancer in Ireland 1-: Annual Report of the National Cancer Registry ABBREVIATIONS % CI % confidence interval APC Annual percentage change ASR Age-standardised rate (European standard population) CNS Central
More informationOverview of 2010 Hong Kong Cancer Statistics
Overview of 2010 Hong Kong Cancer Statistics Cancer Registration in Hong Kong The Hong Kong Cancer Registry has since the 1960s been providing population-based cancer data for epidemiological research
More informationManagement of patients with should not use past or present history of solid cancer
Practical management of patients receiving abatacept 1 Management of patients with should not use past or present history of solid Evidence-based Medicine Official Recommendations Expert opinion Steps
More information2011 to 2015 New Cancer Incidence Truman Medical Center - Hospital Hill
Number of New Cancers Truman Medical Center Hospital Hill Cancer Registry 2015 Statistical Summary Incidence In 2015, Truman Medical Center diagnosed and/or treated 406 new cancer cases. Four patients
More informationPrediction of Cancer Incidence and Mortality in Korea, 2013
pissn 1598-2998, eissn 256 Cancer Res Treat. 213;45(1):15-21 Special Article http://dx.doi.org/1.4143/crt.213.45.1.15 Open Access Prediction of Cancer Incidence and Mortality in Korea, 213 Kyu-Won Jung,
More informationAmerican Cancer Society Estimated Cancer Deaths by Sex and Age (years), 2013
American Cancer Society Estimated Cancer Deaths by Sex and Age (years), 2013 All ages Younger than 45 45 and Older Younger than 65 65 and Older All sites, men 306,920 9,370 297,550 95,980 210,940 All sites,
More informationOverview of 2009 Hong Kong Cancer Statistics
Overview of 2009 Hong Kong Cancer Statistics Cancer Registration in Hong Kong The Hong Kong Cancer Registry has since 1963 been providing population-based cancer data for epidemiological research and healthcare
More informationCancer in New Mexico 2017
Cancer in New Mexico 0 Please contact us! Phone: 0-- E-Mail: nmtr-info@salud.unm.edu URL: nmtrweb.unm.edu TABLE OF CONTENTS Introduction... New Cases of Cancer Estimated Number of New Cancer Cases Description
More informationFull Novartis CTRD Results Template
Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23137E1 Title A
More informationSupplementary Online Content
Supplementary Online Content Acuna SA, Fernandes KA, Daly C, et al. Cancer mortality among recipients of solidorgan transplantation in Ontario, Canada. JAMA Oncol. Published online January 7, 2016. doi:10.1001/jamaoncol.2015.5137
More informationCancer in Rural Illinois, Incidence, Mortality, Staging, and Access to Care. April 2014
Cancer in Rural Illinois, 1990-2010 Incidence, Mortality, Staging, and Access to Care April 2014 Prepared by Whitney E. Zahnd, MS Research Development Coordinator Center for Clinical Research Southern
More informationALL CANCER (EXCLUDING NMSC)
ALL CANCER (EXCLUDING NMSC) AVERAGE NUMBER OF CASES PER YEAR (2012-2016) AVERAGE NUMBER OF DEATHS PER YEAR (2012-2016) Male Female Both sexes Male Female Both sexes 4,607 4,632 9,240 1 2,238 2,036 4,274
More informationCancer in New Mexico 2014
Cancer in New Mexico 2014 Please contact us! Phone: 505-272-5541 E-Mail: info@nmtr.unm.edu http://som.unm.edu/nmtr/ TABLE OF CONTENTS Introduction... 1 New Cases of Cancer: Estimated Number of New Cancer
More informationBrief Update on Cancer Occurrence in East Metro Communities
Brief Update on Cancer Occurrence in East Metro Communities FEBRUARY, 2018 Brief Update on Cancer Occurrence in East Metro Communities Minnesota Department of Health Minnesota Cancer Reporting System PO
More informationCancer in Northeastern Pennsylvania: Incidence and Mortality of Common Cancers
Cancer in Northeastern Pennsylvania: Incidence and Mortality of Common Cancers Samuel M. Lesko, MD, MPH Medical Director Karen Ryczak, RN Surveillance Coordinator December 2014 334 Jefferson Avenue, Scranton,
More informationCancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group
Cancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group Introduction There are more than 200 different types of cancer. It is also referred to as malignancies,
More informationAnnual report on status of cancer in China, 2010
Original Article Annual report on status of cancer in China, 2010 Wanqing Chen, Rongshou Zheng, Siwei Zhang, Ping Zhao, Hongmei Zeng, Xiaonong Zou, Jie He National Office for Cancer Prevention and Control,
More informationGreater Baltimore Medical Center Sandra & Malcolm Berman Cancer Institute
2008 ANNUAL REPORT Greater Baltimore Medical Center Sandra & Malcolm Berman Cancer Institute Cancer Registry Report The Cancer Data Management System/ Cancer Registry collects data on all types of cancer
More informationCancer Facts & Figures for African Americans
Cancer Facts & Figures for African Americans What is the Impact of Cancer on African Americans in Indiana? Table 12. Burden of Cancer among African Americans Indiana, 2004 2008 Average number of cases
More informationOutcomes Report: Accountability Measures and Quality Improvements
Outcomes Report: Accountability Measures and Quality Improvements The FH Memorial Medical Center s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures.
More informationBurden of Cancer in California
Burden of Cancer in California California Cancer Reporting and Epidemiologic Surveillance Institute for Population Health Improvement UC Davis Health August 22, 2018 Outline 1. Incidence and Mortality
More informationPrediction of Cancer Incidence and Mortality in Korea, 2018
pissn 1598-2998, eissn 256 Cancer Res Treat. 218;5(2):317-323 Special Article https://doi.org/1.4143/crt.218.142 Open Access Prediction of Cancer Incidence and Mortality in Korea, 218 Kyu-Won Jung, MS
More informationCancer in Northeastern Pennsylvania: Incidence and Mortality of Common Cancers
Cancer in Northeastern Pennsylvania: Incidence and Mortality of Common Cancers Samuel M. Lesko, MD, MPH Medical Director Karen Ryczak, RN Surveillance Coordinator November 2018 334 Jefferson Avenue, Scranton,
More informationCancer in Northeastern Pennsylvania: Incidence and Mortality of Common Cancers
Cancer in Northeastern Pennsylvania: Incidence and Mortality of Common Cancers Samuel M. Lesko, MD, MPH Medical Director Karen Ryczak, RN Surveillance Coordinator December 2017 334 Jefferson Avenue, Scranton,
More informationCancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group
Cancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group Introduction There are more than 200 different types of cancer. It is also referred to as malignancies,
More informationOutcomes: Initially, our primary definitions of pneumonia was severe pneumonia, where the subject was hospitalized
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationIncidence of Cancers Associated with Modifiable Risk Factors and Late Stage Diagnoses for Cancers Amenable to Screening Idaho
Incidence of Cancers Associated with Modifiable Risk Factors and Late Stage Diagnoses for Cancers Amenable to Screening Idaho 2008-2011 August 2013 A Publication of the Cancer Data Registry of Idaho PO
More informationSKCC Protocol Review Committee New Study Application
Instructions: Submit the following documents to prc@jefferson.edu - Completed New Study Application (aka MCSF) - Protocol - Protocol Facilitation Committee Approval (if applicable) - MDG Priority Score
More informationCancer survival in Seoul, Republic of Korea,
Cancer survival in Seoul, Republic of Korea, 1993 1997 Ahn YO and Shin MH Abstract The Seoul cancer registry was established in 1991. Cancer is a notifiable disease, and registration of cases is done by
More informationNEZ PERCE COUNTY CANCER PROFILE
NEZ PERCE COUNTY CANCER PROFILE A fact sheet from the Cancer Data Registry of Idaho, Idaho Hospital Association. Cancer Incidence 2010-2014 Cancer Mortality 2011-2015 BRFSS 2011-2015 CANCER Cancer is a
More informationKOOTENAI COUNTY CANCER PROFILE
KOOTENAI COUNTY CANCER PROFILE A fact sheet from the Cancer Data Registry of Idaho, Idaho Hospital Association. Cancer Incidence 2010-2014 Cancer Mortality 2011-2015 BRFSS 2011-2015 CANCER Cancer is a
More informationBOUNDARY COUNTY CANCER PROFILE
BOUNDARY COUNTY CANCER PROFILE A fact sheet from the Cancer Data Registry of Idaho, Idaho Hospital Association. Cancer Incidence 2010-2014 Cancer Mortality 2011-2015 BRFSS 2011-2015 CANCER Cancer is a
More informationGSK Clinical Study Register
In February 2013, GlaxoSmithKline (GSK) announced a commitment to further clinical transparency through the public disclosure of GSK Clinical Study Reports (CSRs) on the GSK Clinical Study Register. The
More informationColorectal Cancer Screening
Colorectal Cancer Screening December 5, 2017 Connecticut Cancer Partnership 14th Annual Meeting Xavier Llor, M.D., PhD. Associate Professor of Medicine Co-Director, Cancer Genetics and Prevention Program
More informationEvaluation of Ancestry Information Markers (AIMs) from Previous ACOSOG/CALGB/NCCTG Trials
Evaluation of Ancestry Information Markers (AIMs) from Previous ACOSOG/CALGB/NCCTG Trials Mary Beth Terry, PhD Department of Epidemiology Mailman School of Public Health Racial and Ethnic Disparities in
More informationADAMS COUNTY CANCER PROFILE
ADAMS COUNTY CANCER PROFILE A fact sheet from the Cancer Data Registry of Idaho, Idaho Hospital Association. Cancer Incidence 2010-2014 Cancer Mortality 2011-2015 BRFSS 2011-2015 CANCER Cancer is a group
More informationIncidence of Cancers Associated with Modifiable Risk Factors and Late Stage Diagnoses for Cancers Amenable to Screening Idaho
Incidence of Cancers Associated with Modifiable Risk Factors and Late Stage Diagnoses for Cancers Amenable to Screening Idaho 2009-2012 June 2015 A Publication of the Cancer Data Registry of Idaho PO Box
More informationBONNER COUNTY CANCER PROFILE
BONNER COUNTY CANCER PROFILE A fact sheet from the Cancer Data Registry of Idaho, Idaho Hospital Association. Cancer Incidence 2010-2014 Cancer Mortality 2011-2015 BRFSS 2011-2015 CANCER Cancer is a group
More informationBINGHAM COUNTY CANCER PROFILE
BINGHAM COUNTY CANCER PROFILE A fact sheet from the Cancer Data Registry of Idaho, Idaho Hospital Association. Cancer Incidence 2011-2015 Cancer Mortality 2012-2016 BRFSS 2011-2016 CANCER Cancer is a group
More informationDiagnosing cancer in an emergency: Patterns of emergency presentation of cancer in Ireland
Diagnosing cancer in an emergency: Patterns of emergency presentation of cancer in Ireland 2002 2015 Diagnosing cancer in an emergency: Patterns of emergency presentation of cancer in Ireland 2002 2015
More informationSponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin/Metformin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Study Number CLMF237A2309
More informationCases by year of diagnosis, proportions of further malignancies, deaths, and active follow-up (ALL PATIENTS)
Munich Cancer Registry Survival Selection Matrix Homepage Deutsch ICD-10 D32: Meninges neoplasm Incidence and Mortality Year of diagnosis 1998-2015 Patients 2,545 Diseases 2,547 Creation date 02/01/2018
More informationNEZ PERCE COUNTY CANCER PROFILE
NEZ PERCE COUNTY CANCER PROFILE A fact sheet from the Cancer Data Registry of Idaho, Idaho Hospital Association. Cancer Incidence 2011-2015 Cancer Mortality 2012-2016 BRFSS 2011-2016 CANCER Cancer is a
More informationKOOTENAI COUNTY CANCER PROFILE
KOOTENAI COUNTY CANCER PROFILE A fact sheet from the Cancer Data Registry of Idaho, Idaho Hospital Association. Cancer Incidence 2011-2015 Cancer Mortality 2012-2016 BRFSS 2011-2016 CANCER Cancer is a
More informationTWIN FALLS COUNTY CANCER PROFILE
TWIN FALLS COUNTY CANCER PROFILE A fact sheet from the Cancer Data Registry of Idaho, Idaho Hospital Association. Cancer Incidence 2011-2015 Cancer Mortality 2012-2016 BRFSS 2011-2016 CANCER Cancer is
More informationInformation Services Division NHS National Services Scotland
Cancer in Scotland October 2012 First published in June 2004, revised with each National Statistics publication Next due for revision April 2013 Information Services Division NHS National Services Scotland
More informationRepublican Research and Practical Center for Radiation Medicine and Human Ecology. Ilya Veyalkin Head of Laboratory of Epidemiology Gomel, Belarus
Republican Research and Practical Center for Radiation Medicine and Human Ecology Ilya Veyalkin Head of Laboratory of Epidemiology Gomel, Belarus The contaminated area in the Republic of Belarus consisted
More informationAnnual report on status of cancer in China, 2011
Original Article Annual report on status of cancer in China, 2011 Wanqing Chen, Rongshou Zheng, Hongmei Zeng, Siwei Zhang, Jie He National Office for Cancer Prevention and Control, National Cancer Center,
More informationJEROME COUNTY CANCER PROFILE
JEROME COUNTY CANCER PROFILE A fact sheet from the Cancer Data Registry of Idaho, Idaho Hospital Association. Cancer Incidence 2011-2015 Cancer Mortality 2012-2016 BRFSS 2011-2016 CANCER Cancer is a group
More informationBUTTE COUNTY CANCER PROFILE
BUTTE COUNTY CANCER PROFILE A fact sheet from the Cancer Data Registry of Idaho, Idaho Hospital Association. Cancer Incidence 2011-2015 Cancer Mortality 2012-2016 BRFSS 2011-2016 CANCER Cancer is a group
More informationLINCOLN COUNTY CANCER PROFILE
LINCOLN COUNTY CANCER PROFILE A fact sheet from the Cancer Data Registry of Idaho, Idaho Hospital Association. Cancer Incidence 2011-2015 Cancer Mortality 2012-2016 BRFSS 2011-2016 CANCER Cancer is a group
More informationCANYON COUNTY CANCER PROFILE
CANYON COUNTY CANCER PROFILE A fact sheet from the Cancer Data Registry of Idaho, Idaho Hospital Association. Cancer Incidence 2011-2015 Cancer Mortality 2012-2016 BRFSS 2011-2016 CANCER Cancer is a group
More informationTable E1. Standardized Mortality Ratios for Total and Specific Causes of Death Parameter Radiologists Psychiatrists No. of Deaths
RSNA, 2016 10.1148/radiol.2016152472 Table E1. Standardized Mortality Ratios for Total and Specific Causes of Death Parameter Radiologists Psychiatrists No. of Deaths Observed/Expected No. of Deaths Observed/Expected
More informationCancer A Superficial Introduction
Cancer A Superficial Introduction Gabor Fichtinger, Queen s University Cancer some definitions Medical term: malignant neoplasm Class of diseases in which a group of cells display: uncontrolled growth
More informationWhat is the Impact of Cancer on African Americans in Indiana? Average number of cases per year. Rate per 100,000. Rate per 100,000 people*
What is the Impact of Cancer on African Americans in Indiana? Table 13. Burden of Cancer among African Americans Indiana, 2008 2012 Average number of cases per year Rate per 100,000 people* Number of cases
More informationFull Novartis CTRD Results Template
Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23138E1 Title A
More informationFinal Report 22 January 2014
Final Report 22 January 2014 Cohort Study of Pioglitazone and Cancer Incidence in Patients with Diabetes Mellitus, Follow-up 1997-2012 Kaiser Permanente Division of Research Assiamira Ferrara, MD, Ph.D.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationTrends in Cancer Survival in NSW 1980 to 1996
Trends in Cancer Survival in NSW 19 to 1996 Xue Q Yu Dianne O Connell Bruce Armstrong Robert Gibberd Cancer Epidemiology Research Unit Cancer Research and Registers Division The Cancer Council NSW August
More informationMunich Cancer Registry
Munich Cancer Registry Survival Selection Matrix Homepage Deutsch ICD-10 C64-C68: Urinary tract cancer Incidence and Mortality Year of diagnosis 1998-2016 Patients 23,443 Diseases 24,423 Creation date
More informationMunich Cancer Registry
Munich Cancer Registry Survival Selection Matrix Homepage Deutsch ICD-10 C64: Kidney cancer Incidence and Mortality Year of diagnosis 1998-2016 Patients 11,292 Diseases 11,533 Creation date 08/21/2018
More informationInformation Services Division NHS National Services Scotland
Cancer in Scotland April 2013 First published in June 2004, revised with each National Statistics publication Next due for revision October 2013 Information Services Division NHS National Services Scotland
More informationThe Cancer Burden in California. Janet Bates MD MPH California Cancer Registry California Department of Public Health April 25, 2012
The Cancer Burden in California Janet Bates MD MPH California Cancer Registry California Department of Public Health April 25, 2012 Goals Introduce you to the California Cancer Registry (CCR) Provide an
More informationALL CANCER (EXCLUDING NMSC)
ALL CANCER (EXCLUDING NMSC) AVERAGE NUMBER OF CASES PER YEAR (2011-2015) AVERAGE NUMBER OF DEATHS PER YEAR (2011-2015) Male Female Both sexes Male Female Both sexes 4,557 4,516 9,073 1 2,196 1,984 4,180
More informationCHAPTER 10 CANCER REPORT. Jeremy Chapman. and. Angela Webster
CHAPTER 10 CANCER REPORT Jeremy Chapman and Angela Webster CANCER REPORT ANZDATA Registry 2004 Report This report summarises the cancer (excluding nonmelanocytic skin cancer) experience of patients treated
More informationCancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group
Cancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group Introduction There are more than 200 different types of cancer. It is also referred to as malignancies,
More informationAppendix 1 (as supplied by the authors): Supplementary data
Appendix 1 (as supplied by the authors): Supplementary data I. Cancer prevalence in Canada We obtained 10 year person based cancer prevalence rates for all of Canada for some years of our study period
More informationNICaN workshop: Colorectal Cancer Follow-up
NICaN workshop: Colorectal Cancer Follow-up The Changing Picture of Colorectal Cancer in Northern Ireland Dr Helen Coleman Lecturer in Cancer Epidemiology & CRUK Population Research Postdoctoral Fellow
More informationOverview of 2013 Hong Kong Cancer Statistics
Overview of 2013 Hong Kong Cancer Statistics Cancer Registration in Hong Kong The Hong Kong Cancer Registry (HKCaR) is a population-based cancer registry, collecting the basic demographic data, information
More informationChapter II: Overview
: Overview Chapter II: Overview This chapter provides an overview of the status of cancer in Minnesota, using cases reported to the Minnesota Cancer Surveillance System (MCSS) and deaths reported to the
More informationTrends in Irish cancer incidence with predictions to 2020
Trends in Irish cancer incidence 1994-22 with predictions to 22 Trends in Irish cancer incidence 1994-22 with projections to 22 National Cancer Registry June 26 1 Acknowledgements. I would like to thank
More informationMunich Cancer Registry
Munich Cancer Registry Survival Selection Matrix Homepage Deutsch ICD-10 C70-C72: Brain/nerves cancer Incidence and Mortality Year of diagnosis 1998-2016 Patients 5,904 Diseases 5,912 Creation date 08/21/2018
More informationOverview of Hong Kong Cancer Statistics of 2015
Overview of Hong Kong Cancer Statistics of 2015 This report summarizes the key cancer statistics of Hong Kong for the year of 2015, which is now available on the website of Hong Kong Cancer Registry. Cancer
More informationCancer in Puerto Rico:
Puerto Rico Central Cancer Registry Comprehensive Cancer Center Cancer in Puerto Rico: 2006-2010 Incidence and Mortality Cancer in Puerto Rico 2006-2010 Editors: Guillermo Tortolero Luna, MD, PhD Diego
More informationCancer survival in Shanghai, China,
Cancer survival in Shanghai, China, 1992 1995 Xiang YB, Jin F and Gao YT Abstract The Shanghai cancer registry, established in 1963, is the oldest one in mainland China; cancer registration is entirely
More informationCancer in Maine: Using Data to Direct Actions 2018 Challenge Cancer Conference May 1, 2018
Cancer in Maine: Using Data to Direct Actions 2018 Challenge Cancer Conference May 1, 2018 Tim Cowan, MSPH Director, Data Reporting and Evaluation Center for Health Improvement MaineHealth All Cancer Mortality
More information